Literature DB >> 12406848

Endothelial nitric oxide synthase variants in cystic fibrosis lung disease.

Hartmut Grasemann1, Karin Storm van's Gravesande, Rainer Buscher, Nicola Knauer, Eric S Silverman, Lyle J Palmer, Jeffrey M Drazen, Felix Ratjen.   

Abstract

Variants in the genes encoding for the nitric oxide synthases may act as disease modifier loci in cystic fibrosis, affecting both an individual's nitric oxide level and pulmonary function. In this study, the 894G/T variant in exon 7 of the endothelial nitric oxide synthase gene was related to exhaled nitric oxide and pulmonary function in 70 cystic fibrosis patients who were aged 14.8 +/- 6.9 years (mean +/- SD), with a FEV1 of 69.4 +/- 24.8% predicted. Although there was no association between endothelial nitric oxide synthase genotypes and exhaled nitric oxide in males, nitric oxide levels were significantly higher in female cystic fibrosis patients with an 894T mutant allele, compared with female patients homozygous for the 894G wild-type allele (7.0 +/- 4.4 versus 3.6 +/- 1.9 parts per billion, p = 0.02). Furthermore, in female patients, colonization of airways with Pseudomonas aeruginosa was significantly (p < 0.05) less frequent when carrying an 894T mutant allele as compared with wild type. These data suggest that the 894T variant in the endothelial nitric oxide synthase gene is associated with increased airway nitric oxide formation in female cystic fibrosis patients, possibly affecting colonization of airways with P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406848     DOI: 10.1164/rccm.200202-155OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 2.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 3.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

Review 4.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

5.  Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease.

Authors:  Edward F McKone; Jing Shao; Daisy D Frangolias; Cassie L Keener; Cynthia A Shephard; Federico M Farin; Mark R Tonelli; Peter D Pare; Andrew J Sandford; Moira L Aitken; Terrance J Kavanagh
Journal:  Am J Respir Crit Care Med       Date:  2006-05-11       Impact factor: 21.405

6.  Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension.

Authors:  Jason E Lee; Kirit Patel; Sharilyn Almodóvar; Rubin M Tuder; Sonia C Flores; Pravin B Sehgal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

Review 7.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

Review 8.  Arginase and pulmonary diseases.

Authors:  Harm Maarsingh; Tonio Pera; Herman Meurs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-24       Impact factor: 3.000

9.  CLC-2 single nucleotide polymorphisms (SNPs) as potential modifiers of cystic fibrosis disease severity.

Authors:  Carol J Blaisdell; Timothy D Howard; Augustus Stern; Penelope Bamford; Eugene R Bleecker; O Colin Stine
Journal:  BMC Med Genet       Date:  2004-10-26       Impact factor: 2.103

10.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.